The Basics
What is Iocanlidic Acid I 123?
Used in nuclear medicine for the diagnostic study of thyroid disease.
Brand names for Iocanlidic Acid I 123
Na
How Iocanlidic Acid I 123 is classified
Radiopharmaceuticals, Iodine Radioisotopes, Diagnostic Agents
Iocanlidic Acid I 123 During Pregnancy
Iocanlidic Acid I 123 pregnancy category
Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.
What we know about taking Iocanlidic Acid I 123 while pregnant
N/A
Taking Iocanlidic Acid I 123 While Breastfeeding
What are recommendations for lactation if you're taking Iocanlidic Acid I 123?
Information in this record refers to the use of iocanlidic acid I 123 (123I iodophenylpentadecanoic acid; I 123 IPPA) as a diagnostic agent. The International Commission on Radiological Protection states that breastfeeding should be interrupted for more than 3 weeks following diagnostic use of I 123 IPPA. This usually will result in permanent discontinuation of breastfeeding for this infant.[1] Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[2]
Maternal / infant drug levels
Information in this record refers to the use of iocanlidic acid I 123 (123I iodophenylpentadecanoic acid; I 123 IPPA) as a diagnostic agent. The International Commission on Radiological Protection states that breastfeeding should be interrupted for more than 3 weeks following diagnostic use of I 123 IPPA. This usually will result in permanent discontinuation of breastfeeding for this infant.[1] Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[2]
Possible effects of Iocanlidic Acid I 123 on milk supply
Relevant published information was not found as of the revision date.
Possible alternatives to Iocanlidic Acid I 123
None listed
List of References
Lactation sources: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/1. Mattsson S, Johansson L, Leide Svegborn S et al. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. Annex D. Recommendations on breast-feeding interruptions. Ann ICRP. 2015;44 (2 Suppl):319-21. PMID: 26069086
2. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PMID: 10809203
3. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2. http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/
Disclaimer: This material is provided for educational purposes only and is not intended for medical advice, diagnosis, or treatment. Consult your healthcare provider with any questions.
